- Figure 26
SERVE-HF Trial Design 1
FIG. 26: The SERVE-HF Trial was supported by ResMed with grants from the UK National Institute for Health Research (NIHR) and the US National Institutes of Health (NIH).[15] It enrolled patients with heart failure with LVEF ≤45% on optimal heart failure therapy. Only patients with predominant CSA and an AHI of ³15 were included, and >50% of apnea events had to be central. The sleep studies were done either in a central laboratory with attended polysomnography (PSG) or with laboratory or home polygraphy (PG) without sleep staging, and were scored locally, not in a core laboratory. The denominator for the AHI was recording time rather than sleep time, because with polygraphy it was not possible to record sleep time.
Baseline LVEF was determined retrospectively from historical echocardiograms. This is important, because routine clinical echocardiograms are not usually done to research standard, and from our studies with a core laboratory looking at LVEF measurements, we know that many studies are substandard. This does not imply that the SERVE-HF LVEF readings were substandard, only that it is difficult to evaluate retrospective LVEF measurements recorded for research purposes.
References
Cowie MR, Woehrle H, Wegscheider K, et al. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med. 2015;373:1095–1105.
